Mirtazapine is a prescription antidepressant that doctors sometimes use off-label in dementia when low mood, poor sleep, and poor appetite occur together. It does not reliably improve all three, and dementia trials urge careful, symptom-focused use.
Families often hope one evening pill can calm nights, lift mood, and restore eating at once. Dosing starts at 15 mg each evening, up to 45 mg daily, according to the U.S. National Library of Medicine DailyMed FDA label.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why one pill looks appealing
- Does it lift depression in dementia?
- What about agitation and sleep?
- How to use it more safely
Why one pill looks appealing
Low mood can reduce interest in food and disrupt sleep. A drug that makes people sleepier and hungrier can look like a simple fit for all three problems. Appetite gain is common on mirtazapine, not rare. In U.S.
controlled trials, 17% reported increased appetite versus 2% on placebo, and 7.5% gained at least 7% of body weight versus none on placebo, according to the U.S. National Library of Medicine DailyMed FDA label. Sleepiness is also part of the drug effect. The FDA label warns that somnolence can impair judgment, thinking, and motor skills, which is why the dose goes at bedtime. That same drowsiness raises fall risk and next-day impairment in a person with dementia.
Does it lift depression in dementia?
The largest test did not show benefit for depression in Alzheimer dementia. In the HTA-SADD trial, 326 people with probable or possible Alzheimer disease plus depression received mirtazapine 45 mg, sertraline, or placebo, according to the University of Birmingham record of the Lancet 2011 trial HTA-SADD trial record. Neither active drug beat placebo on Cornell depression scores at 13 or 39 weeks.
Adverse reactions were more common with active treatment. For caregivers, the message is direct. Do not start mirtazapine expecting depression to lift because it works for depression in younger adults. Pick depression as the target only with a clinician, then track mood, interest, sleep, and side effects week by week.
What about agitation and sleep?
Agitation did not improve in the main Alzheimer agitation trial. In SYMBAD, 204 people with Alzheimer disease and agitation that persisted after non-drug care received mirtazapine or placebo, with no significant difference on agitation scores at 12 weeks, according to the LSE Research Online record of the Lancet 2021 trial SYMBAD trial record. The same record reported 7 deaths by week 16 in the mirtazapine group versus 1 in placebo, a marginally significant post-hoc finding.
The authors concluded the data do not support mirtazapine for dementia agitation. Sleep may still feel easier because of sedation, but sedation is not the same as healthy sleep. Added drowsiness can mean more confusion, more falls, and harder mornings without treating the cause of night waking.
How to use it more safely
Start with one clear target symptom, such as weight loss, night waking, or low mood. Agitation should get non-drug care first, with drugs reserved for a defined plan and close follow-up. Use this safety check with the prescriber and pharmacist: Bring a one-week log of sleep, meals, mood, and falls to each visit.
- name the single target and how you will measure it
- review all sedating drugs and fall hazards at home
- track daytime sleepiness, confusion, and falls
- weigh weekly and watch blood sugar, lipids, and swelling
- ask about QT and serotonin interactions with current drugs
